[1]徐进 郑璟 严力军△.黄芪多糖下调骨肉瘤细胞对阿霉素耐药的可能机制研究[J].中国中医骨伤科杂志,2020,28(11):6-9.
　XU Jin ZHENG Jing YAN Lijun.Astragalus Polysaccharide Down-regulates the DrugResistance Mechanism of Osteosarcoma Cells[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2020,28(11):6-9.
点击复制

黄芪多糖下调骨肉瘤细胞对阿霉素耐药的可能机制研究()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第28卷
期数:
2020年11期
页码:
6-9
栏目:
实验研究
出版日期:
2020-11-10

文章信息/Info

Title:
Astragalus Polysaccharide Down-regulates the DrugResistance Mechanism of Osteosarcoma Cells
文章编号:
1005-0205(2020)11-0006-04
作者:
徐进1 郑璟2 严力军1△
1湖北省襄阳市湖北文理学院附属医院(襄阳市中心医院)骨科(湖北 襄阳,441021)2湖北省襄阳市湖北文理学院附属医院(襄阳市中心医院)眼科
Author(s):
XU Jin1 ZHENG Jing2 YAN Lijun1△
1Department of Orthopedics, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang 441021,Hubei China; 2Department of Ophthalmology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang 441021,Hubei China.
关键词:
骨肉瘤;  黄芪多糖;  耐药;  机制
Keywords:
osteosarcoma;  astragalus polysaccharide;  drug resistance;  mechanism
分类号:
R-33
文献标志码:
A
摘要:
目的:研究黄芪多糖下调MG63/ADR耐药骨肉瘤细胞的耐药机制。方法:检测并计算黄芪多糖对MG63骨肉瘤细胞株IC50的影响,将骨肉瘤耐阿霉素细胞株MG63/ADR分为CON组(未行黄芪多糖及阿霉素处理)、APS组(仅黄芪多糖处理)、ADR组(仅阿霉素处理)、A+A组(黄芪多糖联合阿霉素处理),CCK-8法检测细胞吸光度,流式细胞仪检测细胞增殖及凋亡。分别采用RT-PCR和Western Blot法检测四组细胞多药耐药相关蛋白1(MRP-1)和多药耐药1(MDR1)基因mRNA和蛋白质表达。结果:黄芪多糖体外抑制MG63骨肉瘤细胞株IC50为1.6 mg/mL。APS组和CON组、A+A组骨肉瘤耐阿霉素细胞株MG63/ADR的第1～7天吸光度、G0/G1期、S期、G2/M期、增殖指数(PI)、凋亡率、MRP-1和MDR1基因mRNA和蛋白质表达差异无统计学意义(P>0.05)。骨肉瘤耐阿霉素细胞株MG63/ADR的第1～7天吸光度、S期、G2/M期、PI、MRP-1和MDR1基因mRNA和蛋白质表达低于APS组,G0/G1期和凋亡率均高于APS组,差异均有统计学意义(P<0.05)。结论:黄芪多糖可抑制骨肉瘤细胞增殖并促进凋亡,通过抑制MRP-1和MDR1基因表达下调MG63/ADR耐药骨肉瘤细胞对阿霉素的耐药性。
Abstract:
Objective:To study the mechanism of astragalus polysaccharide down-regulating the drug resistance of MG63/ADR-resistant osteosarcoma cells. Methods:CCK-8 method was used to detect the astragalus polysaccharide’s IC50 on MG63/ADR-resistant osteosarcoma cells. MG63/ADR-resistant osteosarcoma cells were divided into CON group(without astragalus polysaccharide and doxorubicin treatment), APS group(astragalus polysaccharide treatment), ADR group(doxorubicin treatment), A+A group(astragalus polysaccharide and doxorubicin treatment). The differences in cell absorbance, cell cycle and apoptosis in four groups were detected and compared. RT-PCR and Western Blot were used to detect the expression of multidrug resistance-associated protein-1(MRP-1)and multidrug resistance-1(MDR-1)mRNA and protein. Results:The astragalus polysaccharide’s IC50 on MG63/ADR-resistant osteosarcoma cells 1.6 mg/mL. The day 1-day 7 absorbance, G0/G1 phase, S phase, G2/M phase, PI, apoptosis rate, MRP-1 and MDR1 expressions of MG63/ADR cell in the APS and CON, A+A groups were not statistically significant(P>0.05). The day 1-day 7 absorbance, S-phase, G2/M-phase,proliferation index(PI), MRP-1 and MDR1 gene mRNA and protein expressions in A+A group were lower than those of APS group, while G0/G1 phase and apoptosis rate were higher than the APS group, and the differences were statistically significant(P<0.05). Conclusion:Astragalus polysaccharides can inhibit the proliferation of osteosarcoma cells and promote apoptosis, and downregulate the resistance of MG63/ADR-resistant osteosarcoma cells to doxorubicin by inhibiting the expression of MRP-1 and MDR1 genes.

参考文献/References:

[1] CHEN R,WANG G,ZHENG Y,et al.Drug resistance-related microRNAs in osteosarcoma:translating basic evidence into therapeutic strategies[J].J Cell Mol Med,2019,23(4):2280-2292.
[2] WAN Y,XU L,ZHUO N,et al.The clinical significance of neoadjuvant chemotherapy in improving the drug resistance of osteosarcoma[J].Minerva Med,2017,108(5):479-481.
[3] 招志辉,丘振文,招远明.黄芪多糖通过调控miR-20a/TGFBR2分子轴降低结直肠癌HT-29/DDP细胞的顺铂耐药性[J].中国肿瘤生物治疗杂志,2019,26(4):417-425.
[4] 刘晓滨,祁丽,张文轩.黄芪多糖逆转EC109/DDP食管癌细胞顺铂耐药的可能机制[J].癌症进展,2017,15(1):29-31.
[5] ROY S,KENNY E,KENNEDY S,et al.MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer[J].Anticancer Res,2007,27(3A):1325-1330.
[6] XIE X,LIU W,DUAN Z,et al.LncRNA NORAD targets miR-410-3p to regulate drug resistance sensitivity of osteosarcoma[J].Cell Mol Biol,2020,66(3):143-148.
[7] TAO Y,XIN M,CHENG H,et al.TRIM37 promotes tumor cell proliferation and drug resistance in pediatric osteosarcoma[J].Oncol Lett,2017,14(6):6365-6372.
[8] CHEN N,KONG Y,WU Y,et al.CAC1 knockdown reverses drug resistance through the downregulation of P-gp and MRP-1 expression in colorectal cancer[J].PLoS One,2019,14(9):e0222035.
[9] ROUNDHILL E A,BURCHILL S A.Detection and characterisation of multi-drug resistance protein 1(MRP-1)in human mitochondria[J].Br J Cancer,2012,106(6):1224-1233.
[10] 聂晓奇,陈治标,徐海涛,等.逆转大鼠胶质瘤细胞耐药性MRP1-siRNA的筛选实验[J].中国临床神经外科杂志,2013,18(3):154-157.
[11] TANAKA K, KIGUCHI K, MIKAMI M,et al.Involvement of the MDR1 gene and glycolipids in anticancer drug-resistance of human ovarian carcinoma-derived cells[J].Hum Cell,2019,32(4):447-452.
[12] LEE P D,NOBLE-TOPHAM S E, BELL R S,et al.Quantitative analysis of multidrug resistance gene expression in human osteosarcomas[J].Br J Cancer,1996,74(7):1046-1050.
[13] YANG S,SUN S,XU W,et al.Astragalus polysaccharide inhibits breast cancer cell migration and invasion by regulating epithelialmesenchymal transition via the Wnt/betacatenin signaling pathway[J].Mol Med Rep,2020,21(4):1819-1832.
[14] SONG J,CHEN Y,HE D,et al.Astragalus polysaccharide promotes adriamycin-induced apoptosis in gastric cancer cells[J].Cancer Manag Res,2020,12:2405-2414.

备注/Memo

备注/Memo:
(收稿日期:2020-06-17)△通信作者 E-mail:winters100@qq.com
更新日期/Last Update: 2020-11-10